STOCK TITAN

Cerevel Therapeutics Holdings, Inc. - CERE STOCK NEWS

Welcome to our dedicated page for Cerevel Therapeutics Holdings news (Ticker: CERE), a resource for investors and traders seeking the latest updates and insights on Cerevel Therapeutics Holdings stock.

Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) is a biopharmaceutical company focused on developing new therapies to treat disorders of the central nervous system (CNS). Formed in 2018 through a partnership between Bain Capital and Pfizer, Cerevel is headquartered in Cambridge, Massachusetts. The company is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases using a differentiated approach that combines expertise in neurocircuitry with a focus on receptor selectivity.

Cerevel's pipeline includes five clinical-stage investigational therapies and several preclinical compounds targeting a range of CNS disorders, such as Parkinson’s disease, Alzheimer’s disease psychosis, epilepsy, schizophrenia, and addiction. The company’s lead programs include:

  • Emraclidine: An M4-selective positive allosteric modulator (PAM) in development for schizophrenia and Alzheimer’s disease psychosis.
  • Darigabat: An α2/3/5-selective GABAA receptor PAM currently under development for epilepsy and panic disorder.
  • Tavapadon: A D1/D5 partial agonist currently in Phase 3 for the treatment of Parkinson’s disease.
  • CVL-871: A D1/D5 partial agonist in development for treatment of dementia-related apathy.

In recent news, Cerevel announced the pricing of its underwritten public offering, where it successfully raised approximately $450 million. Additionally, Cerevel reported positive topline results from its pivotal Phase 3 TEMPO-3 trial for tavapadon as an adjunctive therapy to levodopa in Parkinson’s disease. The company is also advancing its early clinical pipeline and discovery programs while exploring new modalities through internal research, external collaborations, or potential acquisitions.

On December 6, 2023, Cerevel announced its acquisition by AbbVie Inc. (NYSE: ABBV). The transaction, valued at approximately $8.7 billion, aims to bolster AbbVie’s neuroscience portfolio with Cerevel’s robust pipeline of therapies. The acquisition is expected to close by mid-2024, subject to regulatory approvals and other customary conditions.

Cerevel continues to drive forward with its mission, leveraging its deep understanding of neurocircuitry and targeted receptor subtype selectivity to develop innovative treatments for neuroscience diseases, ultimately aiming to improve patient outcomes and quality of life.

Rhea-AI Summary

On May 24, 2024, leading law firm Bleichmar Fonti & Auld LLP (BFA) announced an investigation into the merger between Cerevel Therapeutics (Nasdaq: CERE) and AbbVie. The acquisition deal, valued at $8.7 billion, will see AbbVie purchasing all outstanding Cerevel shares at $45 per share in cash. The boards of both companies have approved the transaction, which is expected to close mid-2024.

BFA is investigating claims that Cerevel's board was conflicted and engaged in an unfair process, potentially undervaluing the shares. Shareholders are encouraged to seek more information about their legal options through BFA's dedicated webpage. Representation is offered on a contingency basis, meaning shareholders incur no costs unless a recovery is made.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.72%
Tags
-
Rhea-AI Summary

Bleichmar Fonti & Auld LLP (BFA) is investigating the merger between Cerevel Therapeutics Holdings and AbbVie, announced on December 6, 2023. AbbVie will acquire all outstanding shares of Cerevel for $45 per share in cash, valuing Cerevel at approximately $8.7 billion. The transaction has been approved by the boards of both companies and is expected to close in mid-2024. BFA is probing into potential conflicts of interest and unfair processes in the decision-making that could have led to an undervaluation of Cerevel’s shares. Shareholders of Cerevel are encouraged to seek legal advice and explore their options.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.05%
Tags
-
Rhea-AI Summary

BFA LLP has announced an investigation into the merger between Cerevel Therapeutics (NASDAQ: CERE) and AbbVie. Under the merger terms, AbbVie will buy all outstanding shares of Cerevel for $45.00 per share in cash, valuing the company at approximately $8.7 billion. This transaction, approved by the boards of directors of both companies, is set to close in mid-2024. BFA LLP suspects that Cerevel's board was conflicted and agreed to an unfair price for shareholders. Shareholders may have legal options and can obtain more information or legal representation on a contingency fee basis by visiting BFA's website or contacting them directly.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.59%
Tags
Rhea-AI Summary
Cerevel Therapeutics announces positive topline results for tavapadon in a Phase 3 adjunctive trial for people living with Parkinson’s disease. The pivotal TEMPO-3 trial showed a significant increase in 'on' time without dyskinesia compared to placebo. Tavapadon demonstrated potential for motor control, safety, and tolerability. Additional data will be presented at future medical meetings, with Phase 3 monotherapy trial results expected in the second half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.3%
Tags
-
Rhea-AI Summary
AbbVie Inc. (NYSE: ABBV) is set to acquire Cerevel Therapeutics (NASDAQ: CERE) for a total equity value of approximately $8.7 billion. The acquisition adds a robust neuroscience pipeline to AbbVie's portfolio, focusing on psychiatric and neurological disorders. The transaction is expected to close in mid-2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.09%
Tags
-
Rhea-AI Summary
Cerevel Therapeutics (Nasdaq: CERE) to Host Tavapadon Investor Webcast for Phase 3 Development in Parkinson’s Disease Treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.44%
Tags
conferences
Rhea-AI Summary
Cerevel Therapeutics (Nasdaq: CERE) to participate in two investor conferences in November with President and CEO Ron Renaud joining fireside chats. Live webcasts and archived versions will be available on the company's investor section website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.2%
Tags
conferences
-
Rhea-AI Summary
Cerevel Therapeutics reported financial results for Q3 2023, raising $499 million from a public offering of common stock. The company's data readout timelines for emraclidine, darigabat, and tavapadon remain on track. Cerevel is well-capitalized with operations supported into 2026. Tavapadon investor webcast scheduled for December 11, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.19%
Tags
-
Rhea-AI Summary
Cerevel Therapeutics to report Q3 2023 financial results and business updates on November 1, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.54%
Tags
conferences earnings
Rhea-AI Summary
Cerevel Therapeutics announces pricing of public offering of common stock
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.67%
Tags

FAQ

What does Cerevel Therapeutics Holdings, Inc. specialize in?

Cerevel Therapeutics specializes in developing new therapies to treat disorders of the central nervous system (CNS), including Parkinson’s, Alzheimer’s, epilepsy, schizophrenia, and addiction.

When was Cerevel Therapeutics formed?

Cerevel Therapeutics was formed in 2018 through a partnership between Bain Capital and Pfizer.

Where is Cerevel Therapeutics headquartered?

Cerevel Therapeutics is headquartered in Cambridge, Massachusetts.

What are some of Cerevel Therapeutics' leading investigational therapies?

Some of Cerevel’s leading investigational therapies include Emraclidine, Darigabat, Tavapadon, and CVL-871.

What is the significance of Cerevel’s recent Phase 3 TEMPO-3 trial results?

The Phase 3 TEMPO-3 trial for tavapadon as an adjunctive therapy to levodopa in Parkinson’s disease met its primary endpoint, showing a clinically meaningful and statistically significant increase in 'on' time without troublesome dyskinesia.

What recent financial achievement has Cerevel accomplished?

Cerevel recently raised approximately $450 million through an underwritten public offering.

What major acquisition was announced involving Cerevel Therapeutics?

On December 6, 2023, AbbVie Inc. announced the acquisition of Cerevel Therapeutics for approximately $8.7 billion.

What is the expected closing date for the AbbVie acquisition of Cerevel?

The acquisition is expected to close in the middle of 2024, pending regulatory approvals and other conditions.

What is Cerevel Therapeutics' approach to treating neuroscience diseases?

Cerevel combines expertise in neurocircuitry with a focus on receptor selectivity to develop innovative treatments for neuroscience diseases.

Who are the contacts for media and investor inquiries at Cerevel Therapeutics?

Anna Robinson is the media contact and Matthew Calistri is the investor contact at Cerevel Therapeutics.

Cerevel Therapeutics Holdings, Inc.

Nasdaq:CERE

CERE Rankings

CERE Stock Data

7.34B
182.20M
15.33%
85.29%
3.49%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
CAMBRIDGE